Ea5142- Adjuvant Nivolumab In Resected Lung Cancers (Anvil)-A Randomized Phase III Study Of Nivolumab After Surgical Resection And Adjuvant Chemotherapy In Non-Small Cell Lung Cancers
Posted Date: May 15, 2019
- Investigator: Muhammad Riaz
- Specialties: Cancer, Lung Cancer, Oncology
- Type of Study: Drug
To evaluate whether adjuvant therapy with nivolumab will result in improved disease-free survival (DFS) over standard observation in patients with Stage IB=4cm, II and IIIA, NSCLC following surgical resection and standard adjuvant therapy.
Criteria:
To Be Eligible: Must Have Nsclc, Age 18 Or Older, Nonpregnant/Breastfeeding, Must Not Have Another Uncontrolled Illness
Keywords:
Lung Cancer, Nsclc, Non-Small Cell Lung , Phase Iii
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com